{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:53:39Z","timestamp":1793840019306,"version":"4.6.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["PO1CA069246"],"award-info":[{"award-number":["PO1CA069246"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,22]]},"DOI":"10.1093\/neuonc\/nox139","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T15:32:14Z","timestamp":1500651134000},"page":"225-235","source":"Crossref","is-referenced-by-count":68,"title":["Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma"],"prefix":"10.1093","volume":"20","author":[{"given":"Maria-Carmela","family":"Speranza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Ricklefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna K","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Kareem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal O","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Bronisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estuardo","family":"Aguilar-Cordova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W","family":"Guzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xandra","family":"Breakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Weissleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0004","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"key\n\t\t\t\t20180122092136_CIT0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"KEYNOTE-024 Investigators","year":"2016","journal-title":"N Engl J Med"},{"issue":"6230","key":"key\n\t\t\t\t20180122092136_CIT0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","year":"2015","journal-title":"Science"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","year":"2016","journal-title":"Cell"},{"issue":"6230","key":"key\n\t\t\t\t20180122092136_CIT0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","year":"2015","journal-title":"Science"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0009","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"key\n\t\t\t\t20180122092136_CIT0010","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0011","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/mthe.2000.0030","article-title":"Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors","volume":"1","year":"2000","journal-title":"Mol Ther"},{"issue":"27","key":"key\n\t\t\t\t20180122092136_CIT0013","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"key\n\t\t\t\t20180122092136_CIT0014","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<267::AID-IJC23>3.0.CO;2-D","article-title":"Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression","volume":"71","year":"1997","journal-title":"Int J Cancer"},{"issue":"1","key":"key\n\t\t\t\t20180122092136_CIT0016","first-page":"e10","article-title":"HMGB1 mediates endogenous TLR2 activation and brain tumor regression","volume":"6","year":"2009","journal-title":"PLoS Med"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm0598-581","article-title":"Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression","volume":"4","year":"1998","journal-title":"Nat Med"},{"issue":"10","key":"key\n\t\t\t\t20180122092136_CIT0018","first-page":"5276","article-title":"Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy","volume":"46","year":"1986","journal-title":"Cancer Res"},{"issue":"8","key":"key\n\t\t\t\t20180122092136_CIT0019","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo","volume":"91","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jnr.490390417","article-title":"Adenovirus-mediated gene therapy of experimental gliomas","volume":"39","year":"1994","journal-title":"J Neurosci Res"},{"issue":"8","key":"key\n\t\t\t\t20180122092136_CIT0021","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/jcb.23126","article-title":"Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development","volume":"112","year":"2011","journal-title":"J Cell Biochem"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0022","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180122092136_CIT0023","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012","volume":"17","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6230","key":"key\n\t\t\t\t20180122092136_CIT0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","year":"2015","journal-title":"Science"},{"issue":"11","key":"key\n\t\t\t\t20180122092136_CIT0025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/neuonc\/nou212","article-title":"Immunotherapy advances for glioblastoma","volume":"16","year":"2014","journal-title":"Neuro Oncol"},{"issue":"19","key":"key\n\t\t\t\t20180122092136_CIT0026","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germLine biallelic mismatch repair deficiency","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t20180122092136_CIT0027","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/neuonc\/now132","article-title":"Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0028","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"key\n\t\t\t\t20180122092136_CIT0029","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneurol.2015.139","article-title":"Prospects of immune checkpoint modulators in the treatment of glioblastoma","volume":"11","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"key\n\t\t\t\t20180122092136_CIT0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","year":"2007","journal-title":"Blood"},{"issue":"7","key":"key\n\t\t\t\t20180122092136_CIT0031","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s13238-016-0281-6","article-title":"Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells","volume":"7","year":"2016","journal-title":"Protein Cell"},{"issue":"4","key":"key\n\t\t\t\t20180122092136_CIT0032","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","article-title":"PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis","volume":"45","year":"2006","journal-title":"J Hepatol"},{"issue":"10","key":"key\n\t\t\t\t20180122092136_CIT0033","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.4049\/jimmunol.1100040","article-title":"The DNA damage response induces IFN","volume":"187","year":"2011","journal-title":"J Immunol"},{"issue":"11","key":"key\n\t\t\t\t20180122092136_CIT0034","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1089\/jir.2006.26.804","article-title":"Blocking monoclonal antibodies specific for mouse IFN-alpha\/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection","volume":"26","year":"2006","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"key\n\t\t\t\t20180122092136_CIT0036","first-page":"171","article-title":"In vitro treatment with ganciclovir restores the functionality of exhausted T cells from cancer patients","year":"2013","journal-title":"Int J Gerontol"},{"issue":"9","key":"key\n\t\t\t\t20180122092136_CIT0037","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1073\/pnas.0931259100","article-title":"PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells","volume":"100","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180122092136_CIT0038","doi-asserted-by":"crossref","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","article-title":"Immunosuppressive mechanisms in glioblastoma","volume":"17","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6","key":"key\n\t\t\t\t20180122092136_CIT0039","first-page":"313","article-title":"Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma","volume":"34","year":"2015","journal-title":"Clin Neuropathol"},{"issue":"7","key":"key\n\t\t\t\t20180122092136_CIT0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","year":"2000","journal-title":"J Exp Med"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0041","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"5256","key":"key\n\t\t\t\t20180122092136_CIT0042","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","year":"1996","journal-title":"Science"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t20180122092136_CIT0044","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0045","doi-asserted-by":"crossref","first-page":"e1117739","DOI":"10.1080\/2162402X.2015.1117739","article-title":"Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression","volume":"5","year":"2016","journal-title":"Oncoimmunology"},{"issue":"6","key":"key\n\t\t\t\t20180122092136_CIT0046","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"341","key":"key\n\t\t\t\t20180122092136_CIT0047","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"key\n\t\t\t\t20180122092136_CIT0048","doi-asserted-by":"crossref","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","year":"2014","journal-title":"PLoS One"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/20\/2\/225\/23602146\/nox139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T09:34:04Z","timestamp":1516613644000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/20\/2\/225\/4004892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,7,24]]},"published-print":{"date-parts":[[2018,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nox139","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,7,24]]}}}